Pozen, Inc., located in Chapel Hill, has received $20 million in milestone payments from GlaxoSmithKline (GSK) for the U.S. Food and Drug Administration (FDA) approval of, and GSK's intent to commercialize, the migraine drug Treximet(TM).
Earlier this month the FDA approved Treximet, a sumatriptan and naproxen sodium combination that provided significantly greater migraine relief in clinical trials compared to treatments using one of the ingredients alone.
GSK will also manufacture the drug, which is expected to arrive in pharmacies by mid-May.
Pozen is a pharmaceutical company that develops therapeutic advancements for diseases with unmet medical needs. Treximet will be Pozen's first marketed product.